


Novel Approaches to Increase Morbillivirus Yield from Eukaryotic Cells In Vitro

A global Fortune 500 company is seeking **novel approaches to increase the viral yield from eukaryotic cell cultures *in vitro***, with particular interest in increasing the yield of Morbilliviruses in established cell lines. Specifically, they are interested in methods to increase the titer of virus propagation during *in vitro* infection, increasing virus secretion or release into cell culture media from infected cells, and/or scalable approaches to concentrate live viral fluids.



Approaches of Interest:

- Novel methods to directly improve the yield of Morbillivirus from any eukaryotic cells *in vitro*, with a focus on cell lines or cells which have potential to be immortalised
- Cell culture media or supplements to increase/enhance viral yield
- Novel approaches to improving yield of related viruses from eukaryotic cells *in vitro*, which can be applied to Morbillivirus

Out of Scope:

- Methods of increasing viral yield which cannot be applied to morbillivirus
- Propagation in non-eukaryotic cells

Developmental Stages of Interest:

- Research with *in vitro* validation or proof of concept are preferred (i.e. data that demonstrate a minimum of 10-fold increase in live virus titer). Early stage research with clear application to the field are also of interest
- Our client is interested in engaging with researchers with expertise in viral propagation that can be applied to improving the yield of morbillivirus from eukaryotic cells *in vitro*




Submission Information

Submission of one page, 200-300 word briefs are encouraged, along with any optional supplementary information e.g. relevant publications. Our client is also open to receiving proposals for novel research projects using this [application form](#). In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets and ongoing research collaboration, funding support for promising research.

Opportunities sought

-  Technologies
-  Academics and expertise
-  Centres of excellence
-  Research projects
-  Spinout companies
-  Biotech assets

Submissions

Please submit relevant, non-confidential opportunities online via: discover.in-part.com

Deadline: **27th November 2023 - 11:59 pm GMT**

Have any questions?

Contact our team at discover@in-part.co.uk